A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

R. K. Kelley, E. Gane, E. Assenat, J. Siebler, P. R. Galle, P. Merle, I. O. Hourmand, A. Cleverly, Y. Zhao, I. Gueorguieva, M. Lahn, S. Faivre, K. A. Benhadji, G. Giannelli

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences